Cas:60078-53-7 2-[2-(methylamino)benzimidazol-1-yl]ethanol manufacturer & supplier

Chemical Name:2-[2-(methylamino)benzimidazol-1-yl]ethanol

CAS.NO:60078-53-7

Synonyms:hms1379e22

Molecular Formula:C₁₀H₁₃N₃O

Molecular Weight:191.23000

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:53.31000

Exact Mass:191.10600

LogP:0.49220

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like hms1379e22 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,hms1379e22 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,hms1379e22 Use and application,hms1379e22 technical grade,usp/ep/jp grade.

Related News: Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality. 2-[2-(methylamino)benzimidazol-1-yl]ethanol manufacturer ��No two studies are the same, and each carries its own unique risks and presents individual challenges, but the aim of CTSuccess is to use the experience we have as a company in supplying materials for thousands of trials to identify the characteristics of a project upfront and highlight potential risk factors that may arise,�� said Kristen Devito, Global Director, Catalent Clinical Supply Services. 2-[2-(methylamino)benzimidazol-1-yl]ethanol supplier The on-body wear is similar to that of an insulin pump. Unlike insulin pump therapy, however, the investigational system is designed such that users enter only their body weight for the iLet to initialize therapy. 2-[2-(methylamino)benzimidazol-1-yl]ethanol vendor This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? 2-[2-(methylamino)benzimidazol-1-yl]ethanol factory Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality.